Samuel Elias Pineda Chavez

Dr. Samuel Elias Pineda Chavez

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2021 in Circulation
Verified
Journal Article
Closed access
PDF file
JMJessica Modica
Jessica Modica
VMVittoria Di Mauro
Vittoria Di Mauro
MBMaria Barandalla-Sobrados
Maria Barandalla-Sobrados
SCSamuel Elias Pineda Chavez
Samuel Elias Pineda Chavez
PCPierluigi Carullo
Pierluigi Carullo
DCDaniele Catalucci
Daniele Catalucci

5 April 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
GRGiulia Rizzo
Giulia Rizzo
SCSamuel Elias Pineda Chavez
Samuel Elias Pineda Chavez
EVElisa Vandenkoornhuyse
Elisa Vandenkoornhuyse
CRCindy Lorena Cárdenas Rincón
Cindy Lorena Cárdenas Rincón
VCValeria Cento
Valeria Cento
SVStefania vetrano
Stefania vetrano
Background: Pomegranate (Punica granatum) can be used to prepare a bioactive extract exerting anti-inflammatory activities. Clinical studies demonstrated an improvement in clinical response in inflammatory bowel disease (IBD) patients when pomegranate extract (PG) was taken as a complement to standard medications. However, the molecular mechanisms underlying its beneficial effects are still scarcely investigated. This study investigates the effect of PG on bacterial biofilm formation and the promotion of mucosal wound healing. Methods: The acute colitis model was induced in C57BL/6N mice by 3% dextran sodium sulfate administration in drinking water for 5 days. During the recovery phase of colitis, mice received saline or PG (200 mg/kg body weight) by oral gavage for 11 days. Colitis was scored daily by evaluating body weight loss, bleeding, and stool consistency. In vivo intestinal permeability was evaluated by fluorescein isothiocyanate-conjugated dextran assay, bacterial translocation was assessed by fluorescence in situ hybridization on tissues, whereas epithelial and mucus integrity were monitored by immunostaining for JAM-A and MUC-2 markers. Bacterial biofilm formation was assessed using microfluidic devices for 24 or 48 h. Primary fibroblasts were isolated from healthy and inflamed areas of 8 IBD patients, and Caco-2 cells were stimulated with or without PG (5 μg/mL). Inflammatory mediators were measured at the mRNA and protein level by RT-PCR, WB, or Bio-plex multiplex immunoassay, respectively. Results: In vivo, PG boosted the recovery phase of colitis, promoting a complete restoration of the intestinal barrier with the regeneration of the mucus layer, as also demonstrated by the absence of bacterial spread into the mucosa and the enrichment of crypt-associated fibroblasts. Microfluidic experiments did not highlight a specific effect of PG on Enterobacterales biofilm formation, even though Citrobacter freundii biofilm was slightly impaired in the presence of PG. In vitro, inflamed fibroblasts responded to PG by downregulating the release of metalloproteinases, IL-6, and IL-8 and upregulating the levels of HGF. Caco-2 cells cultured in a medium supplemented with PG increased the expression of SOX-9 and CD44, whereas in the presence of HGF or plated with a fibroblast-conditioned medium, they displayed a decrease in SOX-9 and CD44 expression and an increase in AXIN2, a negative regulator of Wnt signaling. Conclusions: These data provide new insight into the manifold effects of PG on promoting mucosal homeostasis in IBD by affecting pathogen biofilm formation and favoring the regeneration of the intestinal barrier through the regulation of the crosstalk between epithelial and stromal cells.

19 March 2026 in JCC Plus
Verified
Journal Article
Open access
BRBenedetta Ricchi
Benedetta Ricchi
ALAlejandra Angela Carriles Linares
Alejandra Angela Carriles Linares
SCSamuel Elias Pineda Chavez
Samuel Elias Pineda Chavez
Stefanos BonovasStefanos Bonovas
Stefanos Bonovas
ABArianna Dal Buono
Arianna Dal Buono
SVStefania vetrano
Stefania vetrano
Inflammatory bowel disease (IBD), whose major forms include Crohn's Disease and Ulcerative Colitis, presents significant therapeutic challenge due to its chronic relapsing‐remitting nature. Although pharmacological advances have improved IBD management, many patients either do not respond adequately to available therapies or lose response over time, and thus continue to face unmet clinical needs. This has prompted the exploration of non‐pharmacological strategies aimed at enhancing or complementing therapeutic outcomes. This review offers a comprehensive overview of this evolving paradigm, covering emerging biophysical approaches, including hyperbaric oxygen therapy (HBOT), vagus nerve electrical stimulation (VNS), electromagnetic fields (EMF), low‐intensity pulsed ultrasound (LIPUS), and photobiomodulation (PBM). The analyzed data suggest that while HBOT is most suitable for refractory disease with associated complications, the favorable safety profiles, potential for targeted application, and potent bioeffects of VNS, EMF, LIPUS, and PBM make them particularly promising for future long‐term and combinatory IBD management. The development of standardized protocols and patient stratification biomarkers is identified as a critical next step to facilitate the clinical translation of these emerging technologies.

1 April 2026
Verified
Book Chapter
Closed access
SCSamuel Elias Pineda Chavez
Samuel Elias Pineda Chavez
FHFaris Hrvat
Faris Hrvat
GMGiuseppe Martano
Giuseppe Martano
STSara Timo
Sara Timo
LMLavinia Morosi
Lavinia Morosi
SVStefania Vetrano
Stefania Vetrano